135 related articles for article (PubMed ID: 32012231)
1. Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).
Do YR; Kwak JY; Kim JA; Kim HJ; Chung JS; Shin HJ; Kim SH; Bunworasate U; Choi CW; Zang DY; Oh SJ; Jootar S; Reksodiputro AH; Lee WS; Mun YC; Kong JH; Caguioa PB; Kim H; Park J; Kim DW
Br J Haematol; 2020 Apr; 189(2):303-312. PubMed ID: 32012231
[TBL] [Abstract][Full Text] [Related]
2. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Kwak JY; Kim SH; Oh SJ; Zang DY; Kim H; Kim JA; Do YR; Kim HJ; Park JS; Choi CW; Lee WS; Mun YC; Kong JH; Chung JS; Shin HJ; Kim DY; Park J; Jung CW; Bunworasate U; Comia NS; Jootar S; Reksodiputro AH; Caguioa PB; Lee SE; Kim DW
Clin Cancer Res; 2017 Dec; 23(23):7180-7188. PubMed ID: 28939746
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
Kim SH; Menon H; Jootar S; Saikia T; Kwak JY; Sohn SK; Park JS; Jeong SH; Kim HJ; Kim YK; Oh SJ; Kim H; Zang DY; Chung JS; Shin HJ; Do YR; Kim JA; Kim DY; Choi CW; Park S; Park HL; Lee GY; Cho DJ; Shin JS; Kim DW
Haematologica; 2014 Jul; 99(7):1191-6. PubMed ID: 24705186
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
5. Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.
Noh H; Park MS; Kim SH; Oh SJ; Zang DY; Park HL; Cho DJ; Kim DW; Lee JI
Leuk Lymphoma; 2016 Aug; 57(8):1856-64. PubMed ID: 26666371
[TBL] [Abstract][Full Text] [Related]
6. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Cortes JE; Baccarani M; Guilhot F; Druker BJ; Branford S; Kim DW; Pane F; Pasquini R; Goldberg SL; Kalaycio M; Moiraghi B; Rowe JM; Tothova E; De Souza C; Rudoltz M; Yu R; Krahnke T; Kantarjian HM; Radich JP; Hughes TP
J Clin Oncol; 2010 Jan; 28(3):424-30. PubMed ID: 20008622
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
Pan P; Wang L; Wang Y; Shen L; Zheng P; Bi C; Zhang A; Lv Y; Xue Z; Sun M; Sun C; Li J; Jin L; Yao Y
Acta Haematol; 2020; 143(3):204-216. PubMed ID: 31514197
[TBL] [Abstract][Full Text] [Related]
8. Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
Molica M; Colafigli G; Scalzulli E; Alunni Fegatelli D; Chiatamone Ranieri S; Rizzo L; Diverio D; Efficace F; Latagliata R; Foà R; Breccia M
Ann Hematol; 2019 Aug; 98(8):1891-1904. PubMed ID: 31079264
[TBL] [Abstract][Full Text] [Related]
9. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
10. Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia.
Noh H; Jung SY; Kwak JY; Kim SH; Oh SJ; Zang DY; Lee S; Park HL; Jo DJ; Shin JS; Do YR; Kim DW; Lee JI
Cancer Med; 2018 May; 7(5):1766-1773. PubMed ID: 29577681
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
14. Cellular and molecular responses of Saudi chronic myeloid leukaemia patients to imatinib (STI-571): ten year experience.
Alenzi FQ; Al-Amri AM; Alanazi FG; Tamimi W; Alanazi A; Alenezy AK; Al-Swailmi F
J Ayub Med Coll Abbottabad; 2012; 24(2):122-8. PubMed ID: 24397072
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
17. Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation.
Kim KE; Park S; Cheon S; Kim DY; Cho DJ; Park JM; Hur DY; Park HJ; Cho D
J Immunol Res; 2018; 2018():9580561. PubMed ID: 30687767
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
19. Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.
Lee SE; Choi SY; Kim SH; Song HY; Yoo HL; Lee MY; Hwang HJ; Kang KH; Kee KM; Jang EJ; Kim DW
Leuk Lymphoma; 2018 Jan; 59(1):105-113. PubMed ID: 28540759
[TBL] [Abstract][Full Text] [Related]
20. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
